The committee overruled the reviewers: FDA's advisory panel backs six of seven peptides for the 503A list

Every substance was voted twice. In all seven cases the committee split the same way on the free base and the acetate.

The voting question was identical each time, and the presiding chair read the stakes aloud before each one: a yes recommends that FDA place the substance on the 503A bulks list; a no recommends that it not be placed. The chair also spelled out the consequence of exclusion each time — a substance left off the list once the rule is final stays off-limits to 503A compounders unless some other route opens, either a USP–NF monograph or the substance turning up as a component of an approved drug. FDA's roster lists the committee chairmanship as vacant; Brian Serumaga, PhD, the United States Pharmacopeia's representative, chaired the second day.

Note the shifting denominator. Fifteen members voted on BPC-157, KPV and TB-500; fourteen on MOTS-c, emideltide and semax; only twelve on epitalon. Both days ran long — day one past eleven and a half hours — and the count moved with who was in the room at the time rather than in one direction.

Emideltide lost by a single vote: seven no, six yes, one abstention, on both the free base and the acetate. It is the only substance of the seven that a compounding pharmacy will not be able to point to a favorable committee recommendation for.

The stated reasons cluster tightly. Todd Durham, PhD, of the Foundation Fighting Blindness, said he voted no "primarily for low-quality evidence around efficacy, the poor characterization of the bulk drug substance and the fact that there are approved medical therapies for all proposed uses." That last clause is the one that separated emideltide from the rest: insomnia and narcolepsy have approved treatments, and several members were unwilling to add a poorly characterized substance to the list when a labeled alternative exists.

Kevin Zacharoff, MD, of the Renaissance School of Medicine at Stony Brook University, gave the other recurring reason — he was not persuaded by the argument that legalizing compounded supply would shrink the gray market. If the compounded version cost more, he reasoned, buyers would stay where they are, and the practical effect would be economic rather than protective.

Serumaga, chairing, voted no on characterization grounds: USP's concern is that it is not clear what the bulk drug substance actually is.

Two different questions were being answered in the same room, and much of the friction came from that.

FDA's reviewers applied the four-factor balancing test from the 2019 final rule that set the 503A criteria — characterization, safety, effectiveness, history of use in compounding — and concluded the evidence was too thin on at least two factors for every substance. Several committee members argued that the agency was in practice applying a drug-approval standard to a compounding-eligibility question. Tennessee State Senator Robert Harshbarger III, PharmD, put it directly when he voted yes on emideltide: the duty, as he saw it, was to apply the 503A standards, not the standard for an Investigational New Drug application. A yes vote, he added, does not approve a drug or an indication; it permits patient-specific compounding against a valid prescription.

The other argument that carried weight was substitution. Members who work in clinics described patients arriving with gray-market product of unknown provenance. One physician member, voting yes on BPC-157, described a patient the previous week whose "research grade" material turned out to be adulterated, and conditioned their support on tighter controls — US-sourced APIs, patient registries, mandatory adverse-event reporting. The argument was not confined to clinicians. David Pope, PharmD, chief pharmacy officer at the pharmacy-technology firm XiFin Pharmacy Solutions, framed his yes vote on BPC-157 the same way: "It's time to put this decision in the hands of the patient, the physician and the pharmacist." That is a policy argument about where supply happens rather than a scientific claim about the molecule, and it is not one the balancing test is designed to weigh.

Against that, the dissenters kept returning to the evidence base itself. Elizabeth Rebello, MD, of MD Anderson Cancer Center, voted no on BPC-157 citing the absence of randomized controlled trials and safety concerns. Friedhelm Sandbrink, MD, national program director for pain management at the Veterans Health Administration, voted no on semax and said he did not think the rigorous studies could be skipped when endorsing a product. William Zamboni, PhD, of UPMC Hillman Cancer Center, voted no on epitalon citing a lack of information not only on the product but on how to prescribe it.

There was also an audible gap between what the committee had read and what FDA had reviewed. Haleem Mohammed, MD, global chief medical officer of the men's health clinic network Gameday Men's Health, argued when explaining his yes vote on semax that hundreds of pages of research submitted on time had gone unaddressed. FDA staff countered that the nominators had made the process opaque and that requests for more information had frequently gone nowhere — a point sharpened by the fact that the nominations had been withdrawn altogether, with FDA proceeding at its own discretion. An FDA official told the committee explicitly not to treat the withdrawal as evidence either way.

This part deserves plain description, because it is the part most likely to shape how FDA receives the recommendation.

FDA's published roster, current as of June 29, 2026, lists twelve standing members and a vacant chair. By our count of the affiliations on that roster, six are owners, founders, scientific directors or medical directors of private clinics or clinic networks operating in regenerative medicine, men's health, or longevity — the commercial segment most directly affected by the outcome. They are Gabriel Alizaidy (Maximus Health), Asare Christian (Aether Medicine), Melissa Loseke (Re-New Institute), Haleem Mohammed (Gameday Men's Health), Joshua Starbuck (Makena Health) and Kris Wusterhausen (The Resurge Clinic). All six were appointed in April or May 2026, weeks before this meeting. The remaining members are an anesthesiologist from an academic cancer center, a state senator who is also a pharmacist, a pharmacy-technology executive, the NABP liaison, the USP representative, and a non-voting industry representative from Jazz Pharmaceuticals.

Days before the meeting, FDA added eight temporary voting members. That put nineteen eligible voters in the pool — eleven voting standing members plus the eight temporaries — against a peak turnout of fifteen on any single question, which is where the shifting denominator in section 01 comes from. Trade press reported the additions as a response to conflict-of-interest criticism, and the pattern in the votes is consistent with that: the no votes came predominantly from the academic, federal and standards-body side — Stony Brook, MD Anderson, UPMC, the Veterans Health Administration, USP — while the yes votes came predominantly from clinical practice.

Timothy Fensky, RPh, the National Association of Boards of Pharmacy liaison, abstained on every vote and explained why each time: NABP neither supports nor opposes any peptide's inclusion, the decision rests with FDA, and the association's role — inspection, complaint investigation, discipline — is the same whichever way the agency rules. He urged FDA to use the time before any final rule to build adverse-event reporting infrastructure with the state boards.

Disclosure: one voting member, Gabriel Alizaidy, MD, MS, is listed on FDA's roster as Scientific Director of Maximus Health. He voted yes on emideltide, saying he judged the four relevant criteria to have been met, and yes on epitalon, where he argued there was an immense mismatch between real-world use data and what FDA had presented. Maximus is one of the providers covered in our provider section. PeptideWellness does not accept payment from providers in exchange for placement or scoring. Provider coverage is determined by editorial judgment alone, and Dr. Alizaidy's committee service has no bearing on how Maximus is assessed in our review.

Nothing is legal today that was not legal last week. The committee's recommendations are non-binding. FDA weighs them, finalizes its own reviews, and issues a determination — and there is no published timeline for that step. The 503A bulks list is set by rulemaking, so an actual change in status would arrive as a final rule, not as a press release.

What has changed is the political position of the question. FDA now has a public record in which its own advisory committee, having read the agency's reviews, voted against the agency's proposal twelve times out of fourteen. That is an unusual posture for a compounding decision, and it raises the cost of simply adopting the reviewers' original recommendation. It also sits alongside the April 2026 reclassification that moved twelve peptides out of Category 2 — the direction of travel at the department level is not the same as the direction of travel in the review divisions.

For anyone currently using one of these peptides, the practical position is unchanged from what we wrote last week. A favorable committee vote is not evidence of efficacy, and it is not FDA approval. It is a recommendation about which substances a pharmacy may legally compound from bulk. The questions worth asking a provider are the same ones: which entity compounds the product, under which pathway, what the certificate of analysis says, and what independent evidence supports the specific use being proposed. For the underlying framework, see our compounded vs branded explainer; for how state rules layer on top, see state-by-state access.

FDA has not yet published the meeting minutes or the official transcript; when it does, they will be posted to the meeting page and will supersede the timestamps we have cited here. We will reconcile this page against them. The substantive next step is FDA's own determination, followed — if the agency moves — by proposed and final rulemaking on the 503A list. Neither has a date.